Retinoblastoma secondary prevention

Retinoblastoma Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Retinoblastoma from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Retinoblastoma secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Retinoblastoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Retinoblastoma secondary prevention
CDC on Retinoblastoma secondary prevention
Retinoblastoma secondary prevention in the news
Blogs on Retinoblastoma secondary prevention
Directions to Hospitals Treating Retinoblastoma
Risk calculators and risk factors for Retinoblastoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Secondary prevention strategies following retinoblastoma include cessation of smoking, reduction in sun exposure, and reduction in exposure to ionizing radiation.

Secondary Prevention

Preventive measures to decrease the risk of secondary malignancies in germinal retinoblastoma patients include

• Cessation of smoking
• Reduction in sun exposure
• Reduction in exposure to ionizing radiation (e.g., x-rays and CT scans)
• Children with familial or bilateral retinoblastoma have an increased risk for secondary malignancies elsewhere in the body such as in the skin, soft tissue and bone. Lifelong monitoring for secondary malignancies is advised in these patients.